ESR1 and breast carcinoma: Given the frequent association of ERα-positivity with BMETs, this question is highly relevant for the management of breast cancer, particularly since many ER+ BMETs occur post-hormone therapy (HT) and/or are associated with ligand-independent activating ER mutations[12,13].